Cargando…
Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes
Duodenal mucosal resurfacing (DMR) is a new endoscopic ablation technique aimed at improving glycemia and metabolic control in patients with type 2 diabetes mellitus (T2DM). DMR appears to improve insulin resistance, which is the root cause of T2DM, but its mechanism of action is largely unknown. Bi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Physiological Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858668/ https://www.ncbi.nlm.nih.gov/pubmed/34957857 http://dx.doi.org/10.1152/ajpendo.00337.2021 |
_version_ | 1784654287813476352 |
---|---|
author | Meiring, Suzanne Meessen, Emma C. E. van Baar, Annieke C. G. Holleman, Frits Nieuwdorp, Max Olde Damink, Steven W. Schaap, Frank G. Vaz, Fred M. Groen, Albert K. Soeters, Maarten R. Bergman, Jacques J. G. H. M. |
author_facet | Meiring, Suzanne Meessen, Emma C. E. van Baar, Annieke C. G. Holleman, Frits Nieuwdorp, Max Olde Damink, Steven W. Schaap, Frank G. Vaz, Fred M. Groen, Albert K. Soeters, Maarten R. Bergman, Jacques J. G. H. M. |
author_sort | Meiring, Suzanne |
collection | PubMed |
description | Duodenal mucosal resurfacing (DMR) is a new endoscopic ablation technique aimed at improving glycemia and metabolic control in patients with type 2 diabetes mellitus (T2DM). DMR appears to improve insulin resistance, which is the root cause of T2DM, but its mechanism of action is largely unknown. Bile acids function as intestinal signaling molecules in glucose and energy metabolism via the activation of farnesoid X receptor and secondary signaling [e.g., via fibroblast growth factor 19 (FGF19)], and are linked to metabolic health. We investigated the effect of DMR and glucagon-like peptide-1 (GLP-1) on postprandial bile acid responses in 16 patients with insulin-dependent T2DM, using mixed meal tests performed at the baseline and 6 mo after the DMR procedure. The combination treatment allowed discontinuation of insulin treatment in 11/16 (69%) of patients while improving glycemic and metabolic health. We found increased postprandial unconjugated bile acid responses (all P < 0.05), an overall increased secondary bile acid response (P = 0.036) and a higher 12α-hydroxylated:non-12α-hydroxylated ratio (P < 0.001). Total bile acid concentrations were unaffected by the intervention. Postprandial FGF19 and 7-α-hydroxy-4-cholesten-3-one (C4) concentrations decreased postintervention (both P < 0.01). Our study demonstrates that DMR with GLP-1 modulates the postprandial bile acid response. The alterations in postprandial bile acid responses may be the result of changes in the microbiome, ileal bile acid uptake and improved insulin sensitivity. Controlled studies are needed to elucidate the mechanism linking the combination treatment to metabolic health and bile acids. NEW & NOTEWORTHY Glycemic and metabolic improvements are seen in patients with type 2 diabetes after replacing their insulin therapy with DMR and GLP-1. These changes are accompanied by changes in postprandial bile acid concentrations: increased unconjugated and secondary bile acids. |
format | Online Article Text |
id | pubmed-8858668 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Physiological Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-88586682022-03-03 Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes Meiring, Suzanne Meessen, Emma C. E. van Baar, Annieke C. G. Holleman, Frits Nieuwdorp, Max Olde Damink, Steven W. Schaap, Frank G. Vaz, Fred M. Groen, Albert K. Soeters, Maarten R. Bergman, Jacques J. G. H. M. Am J Physiol Endocrinol Metab Research Article Duodenal mucosal resurfacing (DMR) is a new endoscopic ablation technique aimed at improving glycemia and metabolic control in patients with type 2 diabetes mellitus (T2DM). DMR appears to improve insulin resistance, which is the root cause of T2DM, but its mechanism of action is largely unknown. Bile acids function as intestinal signaling molecules in glucose and energy metabolism via the activation of farnesoid X receptor and secondary signaling [e.g., via fibroblast growth factor 19 (FGF19)], and are linked to metabolic health. We investigated the effect of DMR and glucagon-like peptide-1 (GLP-1) on postprandial bile acid responses in 16 patients with insulin-dependent T2DM, using mixed meal tests performed at the baseline and 6 mo after the DMR procedure. The combination treatment allowed discontinuation of insulin treatment in 11/16 (69%) of patients while improving glycemic and metabolic health. We found increased postprandial unconjugated bile acid responses (all P < 0.05), an overall increased secondary bile acid response (P = 0.036) and a higher 12α-hydroxylated:non-12α-hydroxylated ratio (P < 0.001). Total bile acid concentrations were unaffected by the intervention. Postprandial FGF19 and 7-α-hydroxy-4-cholesten-3-one (C4) concentrations decreased postintervention (both P < 0.01). Our study demonstrates that DMR with GLP-1 modulates the postprandial bile acid response. The alterations in postprandial bile acid responses may be the result of changes in the microbiome, ileal bile acid uptake and improved insulin sensitivity. Controlled studies are needed to elucidate the mechanism linking the combination treatment to metabolic health and bile acids. NEW & NOTEWORTHY Glycemic and metabolic improvements are seen in patients with type 2 diabetes after replacing their insulin therapy with DMR and GLP-1. These changes are accompanied by changes in postprandial bile acid concentrations: increased unconjugated and secondary bile acids. American Physiological Society 2022-02-01 2021-12-27 /pmc/articles/PMC8858668/ /pubmed/34957857 http://dx.doi.org/10.1152/ajpendo.00337.2021 Text en Copyright © 2022 The Authors https://creativecommons.org/licenses/by/4.0/Licensed under Creative Commons Attribution CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/) . Published by the American Physiological Society. |
spellingShingle | Research Article Meiring, Suzanne Meessen, Emma C. E. van Baar, Annieke C. G. Holleman, Frits Nieuwdorp, Max Olde Damink, Steven W. Schaap, Frank G. Vaz, Fred M. Groen, Albert K. Soeters, Maarten R. Bergman, Jacques J. G. H. M. Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes |
title | Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes |
title_full | Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes |
title_fullStr | Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes |
title_full_unstemmed | Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes |
title_short | Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes |
title_sort | duodenal mucosal resurfacing with a glp-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858668/ https://www.ncbi.nlm.nih.gov/pubmed/34957857 http://dx.doi.org/10.1152/ajpendo.00337.2021 |
work_keys_str_mv | AT meiringsuzanne duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes AT meessenemmace duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes AT vanbaaranniekecg duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes AT hollemanfrits duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes AT nieuwdorpmax duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes AT oldedaminkstevenw duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes AT schaapfrankg duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes AT vazfredm duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes AT groenalbertk duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes AT soetersmaartenr duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes AT bergmanjacquesjghm duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes |